Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.45 |
| ▸ | NPY1R | P25929 | 6/20 | 0.45 |
| ▸ | NPY2R | P49146 | 4/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | FNTA | P49354 | 3/20 | 0.43 |
| ▸ | FNTB | P49356 | 3/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29511121 | 0.98 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RCTSL | |
| SCHEMBL31620050 | 0.93 | CTSL (0.46) | NPY4RNPY1RNPY2RNPY5RCTSL | |
| SCHEMBL30045207 | 0.92 | FNTA (0.47) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL29482503 | 0.92 | FNTA (0.51) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL29511195 | 0.92 | FNTA (0.51) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL29511116 | 0.90 | FNTA (0.47) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL29511047 | 0.89 | C5AR1 (0.50) | NPY4RNPY1RNPY2RC5AR1 | |
| SCHEMBL30725662 | 0.88 | APLNR (0.45) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL29476479 | 0.88 | FNTA (0.49) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL31252942 | 0.87 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | claimed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | claimed |
| EP-4711004-A2 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |